Cannabinoid Signalling Group
The Cannabinoid Signalling Group belongs to the Department of Biochemistry and Molecular Biology at the Schools of Chemistry and Biology of the Complutense University of Madrid, and it is coordinated by Manuel Guzmán. Nowadays, Ismael Galve-Roperh, Cristina Sánchez and Guillermo Velasco lead three of the ongoing research lines in our group.
Cannabinoid Signalling Group
The major focus of our group is the study of the mechanisms by which cannabinoids – the active components of Cannabis sativa L. – and their endogenous counterparts control the proliferation, differentiation and survival of different types of cells.
These are our research lines:
Recent publications
Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer (2019)
Blasco-Benito, S. et al.
For more publications from Breast Cancer, click here.
Δ9-Tetrahydrocannabinol promotes functional remyelination in the mouse brain (2021)
Aguado, T., Huerga-Gómez, A. et al.
Para ver más publicaciones del grupo de Neurogénesis, haz click aquí.
Identification of BiP as a CB 1 receptor-interacting protein that fine-tunes cannabinoid signaling in the mouse brain (2021)
Costas-Insua, C. et al.
For more publications from Neuroprotection, click here.
The Pseudokinase TRIB3 Negatively Regulates the HER2 Receptor Pathway and Is a Biomarker of Good Prognosis in Luminal Breast Cancer (2021)
Orea-Soufi, A. et al.
For more publications from Brain Tumors, click here.
Acknowledgements
Our group acknowledges the support of funding institutions, both public and private.
